| Indicators to assess aggregate RACF-level concordance | Corresponding Guideline recommendations |
---|---|---|
1 | Residents using antipsychotics have documentation of experiencing distressing psychotic symptoms and/or aggression/agitation within the past 12 weeks that represents a direct threat to either the resident or other residents, staff, or family for the resident’s prescription of the antipsychotic | GPS 9; CR 3 |
2 | Residents using antipsychotics have documentation of individually targeted non-pharmacological management strategies to manage distressing psychotic symptoms and/or aggression/agitation that are currently in place | GPS 6 |
3 | Residents using antipsychotics are using a second-generation antipsychotic | CR 1 |
4 | Residents using antipsychotics have documentation of informed consent for use of the antipsychotic | GPS 8 |
5 | Residents using antipsychotics have a documented date of next review for antipsychotic treatment effectiveness | GPS 10 |
6 | Residents using antipsychotics have a current antipsychotic adverse event monitoring protocol in place | GPS 20 |
7 | Residents using antipsychotics have used the current antipsychotic for less than 12Â weeks | GPS 19; GPS 21 |
8 | Residents using antipsychotics for more than 12Â weeks are currently having the antipsychotic dose tapered | GPS 19; GPS 23 |
9 | Residents using antipsychotics for more than 12Â weeks and not currently tapering have documentation that the resident has been reviewed by either a psychiatrist or geriatrician, a formal documented discussion between the prescriber and a psychiatrist or geriatrician in which both practitioners agree or a documented clinical review involving the prescriber and at least one other medical practitioner in which both practitioners agree | GPS 19; GPS 21; GPS 22 |